- Home
- MODD vs CYCC Comparison
MODD vs CYCC Comparison
Compare MODD & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CYCC
- Stock Information
- Founded
- MODD 1998
- CYCC 1992
- Country
- MODD United States
- CYCC Malaysia
- Employees
- MODD N/A
- CYCC N/A
- Industry
- MODD Industrial Specialties
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- CYCC Health Care
- Exchange
- MODD Nasdaq
- CYCC Nasdaq
- Market Cap
- MODD 46.3M
- CYCC 61.2M
- IPO Year
- MODD N/A
- CYCC N/A
- Fundamental
- Price
- MODD $0.86
- CYCC $1.63
- Analyst Decision
- MODD
- CYCC
- Analyst Count
- MODD 0
- CYCC 0
- Target Price
- MODD N/A
- CYCC N/A
- AVG Volume (30 Days)
- MODD 78.5K
- CYCC 191.0K
- Earning Date
- MODD 06-20-2025
- CYCC 05-15-2025
- Dividend Yield
- MODD N/A
- CYCC 147.24%
- EPS Growth
- MODD N/A
- CYCC N/A
- EPS
- MODD N/A
- CYCC N/A
- Revenue
- MODD N/A
- CYCC $14,000.00
- Revenue This Year
- MODD N/A
- CYCC $137.21
- Revenue Next Year
- MODD N/A
- CYCC N/A
- P/E Ratio
- MODD N/A
- CYCC N/A
- Revenue Growth
- MODD N/A
- CYCC N/A
- 52 Week Low
- MODD $0.68
- CYCC $1.36
- 52 Week High
- MODD $2.65
- CYCC $49.34
- Technical
- Relative Strength Index (RSI)
- MODD 39.61
- CYCC 32.89
- Support Level
- MODD $0.75
- CYCC $1.36
- Resistance Level
- MODD $0.90
- CYCC $1.94
- Average True Range (ATR)
- MODD 0.07
- CYCC 0.43
- MACD
- MODD -0.01
- CYCC -0.07
- Stochastic Oscillator
- MODD 39.29
- CYCC 8.31
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.